Prognostic potential of a PSA complex in sera of prostate cancer patients with α2-macroglobulin deficiency

Journal of Clinical Laboratory Analysis

Volumn 22, Issue 4, 2008, Pages 302-306

  Kanoh, Yuhsaku ^a,d   Ohara, Tadashi ^b   Egawa, Shin ^c   Baba, Shiro ^a   Akahoshi, Tohru ^a  

^a KITASATO UNIVERSITY   (Japan)

^b International University of Health and Welfare Hospital   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1 antichymotrypsin; 2 macroglobulin deficiency; Prostate specific antigen

Indexed keywords

ALPHA 2 MACROGLOBULIN; CHYMOTRYPSIN INHIBITOR; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LASER NEPHELOMETRY; MALE; PATIENT MONITORING; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; RADIOIMMUNOASSAY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALPHA-MACROGLOBULINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 48249113314     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20260     Document Type: Article

References (24)

1. Kenneth WKW, Paul JL, Thabiso MT, Wai PC, Rueywing L. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170.
2. Uwe T, Thomas Q, Folkert D, Astrid L, Radoff D. Biological activity of prostate-specific antigen isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroelution. Electrophoresis 1995;16:793-799.
3. Deborah SS, Peter AH, William JC. The early detection of prostate carcinoma with prostate specific antigen. Cancer 1997;80:1852-1856.
4. Reinhard S, Mirtha G, Kjell C, Bernhard T, Ake P. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000;6:160-165.
5. Anthony VDA, Richard W, Detray S, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000;18:1164-1172.
6. Anders C, Thomas B, Olle N, et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as indicator of prostate cancer. J Urol 1993;150:100-105.
7. Mary JH, Francisco E, Ruben FG, John HG. Prostate specific antigen-α2macroglobulin complexes in prostate cancer patient sera. Biochem Mol Biol Int 1995;37:917-923.
8. Ann MZ, Prakash CT, Barry IB, George WC, Fred LL. Multiple form of prostate-specific antigen in serum: Differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993;39:2483-2491.
9. Albert AL, Yating C, Thomas FS, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Adult Urol 1995;46:187-196.
10. Klaus J, Brigitte B, Michael L, et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: Biochemical and diagnostic implications. Clin Chem 2000;46:47-54.
11. Klaus J, Ulrike E, Michael L, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000;46:55-62.
12. 2-macroglobulin as a carrier protein for IL-6. J Immunol 1989;142:148-152.
13. 2-macroglobulin as a growth hormone-binding protein in human blood. J Clin Endocrinol Metab 1995;80:585-590.
14. Ohtani H, Saito M, Koshiba K. Alpha-2-macroglobulin deficiency in patients with advanced prostate cancer. Oncology 1985;42:341-344.
15. 2- macroglobulin deficiency in association with cancer metastasis. Jpn J Clin Immun 1997;20:30-43.
16. International Union Against Cancer. 1992. In: B Spiessl, OH Beahrs, P Hermanek, et al, editors. TNM Atlas, third edition, second revision. New York: Springer-Verlag. p 241-250.
17. 2- macroglobulin. J Biol Chem 1991;266:12329-12336.
18. Debanne MT, Regoeczl E, Dolovich J. Serum prostate inhibitors in the blood clearance of subtilisin A. Br J Exp Pathol 1973;54:571-582.
19. Katayama K, Fujita T. Studies on biotransformation of clastase III. Effects of elastase-binding proteins in serum on the disappearance of 131I-labeled elastase from blood. Biochim Biophys Acta 1974;336:165-177.
20. Kanoh Y, Ohtani N, Ohara T, et al. Progression of prostate cancer: Diagnostic and prognostic utility of prostate-specific antigen, α2-macrogloburin, and their complexes. Oncol Rep 2001;8:515-519.
21. Ulf-Hakan S, Jari L, Henrik A, Sakari R, Kari T, Olof A. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
22. Saika T, Tsushima T, Nasu Y, et al. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. Cancer 2002;94:1685-1691.
23. Kuvibidila S, Rayford W. Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer. J Lab Clin Med 2006;147:174-181.
24. Kikuchi E, Nakashima J, Ishibashi M, et al. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer. Urology 2006;68:371-375.